JP2011503199A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503199A5
JP2011503199A5 JP2010534194A JP2010534194A JP2011503199A5 JP 2011503199 A5 JP2011503199 A5 JP 2011503199A5 JP 2010534194 A JP2010534194 A JP 2010534194A JP 2010534194 A JP2010534194 A JP 2010534194A JP 2011503199 A5 JP2011503199 A5 JP 2011503199A5
Authority
JP
Japan
Prior art keywords
heterocyclic
condensed
nhr
benzene
cycloalkane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010534194A
Other languages
English (en)
Japanese (ja)
Other versions
JP5450434B2 (ja
JP2011503199A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/083478 external-priority patent/WO2009064938A1/en
Publication of JP2011503199A publication Critical patent/JP2011503199A/ja
Publication of JP2011503199A5 publication Critical patent/JP2011503199A5/ja
Application granted granted Critical
Publication of JP5450434B2 publication Critical patent/JP5450434B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010534194A 2007-11-16 2008-11-14 関節炎の治療方法 Expired - Fee Related JP5450434B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98847907P 2007-11-16 2007-11-16
US60/988,479 2007-11-16
PCT/US2008/083478 WO2009064938A1 (en) 2007-11-16 2008-11-14 Method of treating arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013232754A Division JP5667684B2 (ja) 2007-11-16 2013-11-11 関節炎の治療方法

Publications (3)

Publication Number Publication Date
JP2011503199A JP2011503199A (ja) 2011-01-27
JP2011503199A5 true JP2011503199A5 (cg-RX-API-DMAC7.html) 2012-01-05
JP5450434B2 JP5450434B2 (ja) 2014-03-26

Family

ID=40291332

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010534194A Expired - Fee Related JP5450434B2 (ja) 2007-11-16 2008-11-14 関節炎の治療方法
JP2013232754A Expired - Fee Related JP5667684B2 (ja) 2007-11-16 2013-11-11 関節炎の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013232754A Expired - Fee Related JP5667684B2 (ja) 2007-11-16 2013-11-11 関節炎の治療方法

Country Status (14)

Country Link
US (2) US20090176785A1 (cg-RX-API-DMAC7.html)
EP (1) EP2231159A1 (cg-RX-API-DMAC7.html)
JP (2) JP5450434B2 (cg-RX-API-DMAC7.html)
KR (1) KR101585848B1 (cg-RX-API-DMAC7.html)
CN (1) CN101969951B (cg-RX-API-DMAC7.html)
AU (1) AU2008322595B2 (cg-RX-API-DMAC7.html)
CA (1) CA2705294C (cg-RX-API-DMAC7.html)
DO (1) DOP2013000169A (cg-RX-API-DMAC7.html)
IL (2) IL205501A (cg-RX-API-DMAC7.html)
MX (1) MX2010005395A (cg-RX-API-DMAC7.html)
NZ (2) NZ601350A (cg-RX-API-DMAC7.html)
RU (2) RU2526201C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009064938A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201003434B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
SI2550258T1 (sl) * 2010-03-25 2016-01-29 Abbvie Inc. Sredstva za induciranje apoptoze pri zdravljenju raka ter imunskih in avtoimunskih obolenj
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
UY33746A (es) 2010-11-23 2012-06-29 Abbott Lab Método de tratamiento que usa inhibidores selectivos de bcl-2
SI2643322T1 (en) 2010-11-23 2018-01-31 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR102705861B1 (ko) 2017-08-23 2024-09-10 광조우 루펭 파마슈티칼 컴퍼니 엘티디. Bcl-2 억제제
WO2020041405A1 (en) 2018-08-22 2020-02-27 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021066873A1 (en) 2019-10-03 2021-04-08 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
PH12022551091A1 (en) 2019-11-05 2024-06-24 Abbvie Deutschland Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
EP4110298A1 (en) 2020-02-24 2023-01-04 Guangzhou Lupeng Pharmaceutical Company Ltd. Hot melt extruded solid dispersions containing a bcl2 inhibitor
US20240166646A1 (en) 2020-12-22 2024-05-23 Newave Pharmaceutical Inc. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
EP0863873B1 (en) * 1995-10-10 1999-11-10 Pfizer Inc. Indole carbamates as leukotriene antagonists
AU2001245891A1 (en) * 2000-03-21 2001-10-03 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
KR100600550B1 (ko) * 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
GB0217431D0 (en) * 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
CN1856490A (zh) * 2003-07-28 2006-11-01 詹森药业有限公司 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用
AU2004268839A1 (en) * 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
ES2257929B1 (es) * 2004-07-16 2007-05-01 Laboratorios Del Dr. Esteve, S.A. Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
CA2606147C (en) * 2005-05-12 2011-07-05 Abbott Laboratories Apoptosis promoters
US20060276464A1 (en) * 2005-05-13 2006-12-07 Wyeth Diarylsulfone sulfonamides and use thereof
WO2008064116A2 (en) * 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection

Similar Documents

Publication Publication Date Title
JP2011503199A5 (cg-RX-API-DMAC7.html)
RU2012143212A (ru) Способ лечения артрита
RU2011134634A (ru) Индуцирующие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
JP5517935B2 (ja) 細胞壊死阻害剤としてのインドール及びインダゾール化合物
AU2016256728B2 (en) Thiadiazole analogs thereof and methods for treating smn-deficiency-related-conditions
JP2014511869A5 (cg-RX-API-DMAC7.html)
JP2016517878A5 (cg-RX-API-DMAC7.html)
RU2356893C2 (ru) Ингибиторы фосфодиэстеразы 4
JP2014501732A5 (cg-RX-API-DMAC7.html)
JP2005526723A5 (cg-RX-API-DMAC7.html)
JP2012522003A5 (cg-RX-API-DMAC7.html)
JP2016540742A5 (cg-RX-API-DMAC7.html)
RU2012156940A (ru) Лекарственные средства, индуцирующие апоптоз, для лечения рака и иммунных и аутоиммунных заболеваний
RU2011134631A (ru) Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
JP2008513515A5 (cg-RX-API-DMAC7.html)
JP2014521653A5 (cg-RX-API-DMAC7.html)
JP2018526413A5 (cg-RX-API-DMAC7.html)
JP2016530322A5 (cg-RX-API-DMAC7.html)
JP2013532709A5 (cg-RX-API-DMAC7.html)
RU2012107101A (ru) Производные пирроло[1,2-в] пиридазина как ингибиторы янус-киназы
JP2014518869A5 (cg-RX-API-DMAC7.html)
RU2015111133A (ru) Ингибиторы тирозинкиназы брутона
JP2016540771A5 (cg-RX-API-DMAC7.html)
JP2010527985A5 (cg-RX-API-DMAC7.html)
JP2019535825A5 (cg-RX-API-DMAC7.html)